IOTECH in times of COVID-19

od Haanen, J.
izdano v Immunooncol Technol (2020)

IOTECH in times of COVID-19

od Haanen, J.B.
izdano v Immunooncol Technol (2020)

Tumor‐infiltrating lymphocytes for the treatment of metastatic cancer

od Geukes Foppen, M.H., Donia, M., Svane, I.M., Haanen, J.B.A.G.
izdano v Mol Oncol (2015)

Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma

od Groenewegen, G, Walraven, M, Vermaat, J, de Gast, B, Witteveen, E, Giles, R, Haanen, J, Voest, E
Izdano 2012

Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

od van der Veldt, A A M, Boven, E, van den Eertwegh, A J M, Haanen, J B A G
Izdano 2009

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

od van der Veldt, A A M, Meijerink, M R, van den Eertwegh, A J M, Haanen, J B A G, Boven, E
Izdano 2010

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry

od De Groot, S., Sleijfer, S., Redekop, W. K., Oosterwijk, E., Haanen, J. B. A. G., Kiemeney, L. A. L. M., Uyl-de Groot, C. A.
izdano v BMC Cancer (2016)

T-cell receptor beta-chain gene usage in the T-cell recognition of Mycobacterium leprae antigens in one tuberculoid leprosy patient.

od van Schooten, W C, Ko, J L, van der Stoep, N, Haanen, J B, Pickering, L, de Vries, R R, van den Elsen, P
Izdano 1992

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer

od Powles, T., Kayani, I., Blank, C., Chowdhury, S., Horenblas, S., Peters, J., Shamash, J., Sarwar, N., Boletti, K., Sadev, A., O'Brien, T., Berney, D., Beltran, L., Haanen, J., Bex, A.
Izdano 2011

Cryoablation and immunotherapy: an overview of evidence on its synergy

od Aarts, B. M., Klompenhouwer, E. G., Rice, S. L., Imani, F., Baetens, T., Bex, A., Horenblas, S., Kok, M., Haanen, J. B. A. G., Beets-Tan, R. G. H., Gómez, F. M.
izdano v Insights Imaging (2019)

Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma

od Vyth-Dreese, F A, Sein, J, van de Kasteele, W, Dellemijn, T A M, van den Bogaard, C, Nooijen, W J, de Gast, G C, Haanen, J B A G, Bex, A
Izdano 2010

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

od Curigliano, G., Banerjee, S., Cervantes, A., Garassino, M.C., Garrido, P., Girard, N., Haanen, J., Jordan, K., Lordick, F., Machiels, J.P., Michielin, O., Peters, S., Tabernero, J., Douillard, J.Y., Pentheroudakis, G.
izdano v Ann Oncol (2020)

Myelosuppression by sunitinib is flt-3 genotype dependent

od van Erp, N P, Mathijssen, R H J, van der Veldt, A A, Haanen, J B, Reyners, A K L, Eechoute, K, Boven, E, Wessels, J A M, Guchelaar, H-J, Gelderblom, H
Izdano 2010

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

od van der Veldt, A A M, Boven, E, Helgason, H H, van Wouwe, M, Berkhof, J, de Gast, G, Mallo, H, Tillier, C N, van den Eertwegh, A J M, Haanen, J B A G
Izdano 2008

The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration

od Banerjee, S., Lim, K.H.J., Murali, K., Kamposioras, K., Punie, K., Oing, C., O'Connor, M., Thorne, E., Devnani, B., Lambertini, M., Westphalen, C.B., Garrido, P., Amaral, T., Morgan, G., Haanen, J.B.A.G., Hardy, C.
izdano v ESMO Open (2021)

The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II

od Lim, K.H.J., Murali, K., Kamposioras, K., Punie, K., Oing, C., O’Connor, M., Thorne, E., Amaral, T., Garrido, P., Lambertini, M., Devnani, B., Westphalen, C.B., Morgan, G., Haanen, J.B.A.G., Hardy, C., Banerjee, S.
izdano v ESMO Open (2021)

LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration

od Banerjee, S., Lim, K.H.J., Kamposioras, K.V., Murali, K., Oing, C., Punie, K., O'Connor, M., Devnani, B., Lambertini, M., Benedikt Westphalen, C., Garrido Lopez, P., Amaral, T.M.S., Thorne, E., Morgan, G., Haanen, J.B.A.G., Hardy, C.
izdano v Ann Oncol (2020)

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey

od Garrido, P., Adjei, A.A., Bajpai, J., Banerjee, S., Berghoff, A.S., Choo, S.P., Felip, E., Furness, A.J.S., Garralda, E., Haanen, J., Letsch, A., Linardou, H., Peters, S., Sessa, C., Tabernero, J., Tsang, J., Yang, J.C-.H., Garassino, M.C.
izdano v ESMO Open (2021)

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

od Chapman, P B, Robert, C, Larkin, J, Haanen, J B, Ribas, A, Hogg, D, Hamid, O, Ascierto, P A, Testori, A, Lorigan, P C, Dummer, R, Sosman, J A, Flaherty, K T, Chang, I, Coleman, S, Caro, I, Hauschild, A, McArthur, G A
izdano v Ann Oncol (2017)

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

od Gore, M E, Szczylik, C, Porta, C, Bracarda, S, Bjarnason, G A, Oudard, S, Lee, S-H, Haanen, J, Castellano, D, Vrdoljak, E, Schöffski, P, Mainwaring, P, Hawkins, R E, Crinò, L, Kim, T M, Carteni, G, Eberhardt, W E E, Zhang, K, Fly, K, Matczak, E, Lechuga, M J, Hariharan, S, Bukowski, R
izdano v Br J Cancer (2015)